Serum Institute of India & Moderna
4 shared events · Importance 3 · Last updated Aug 18, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Tech
Serum Institute of India: The Serum Institute of India is manufacturing a vaccine candidate developed by the University of Oxford, receiving up to $8.6 million from CEPI for its development.
Moderna: Moderna received up to $50 million from CEPI to support the preclinical and early clinical development of its mRNA-based Ebola Bundibugyo vaccine candidate, leveraging its mRNA platform for rapid response.
May 22, 2026 · 36 articles
Accidents
Serum Institute of India: Manufactured 620,000 doses of the Oxford vaccine candidate, positioning itself for large-scale production if trials succeed.
Moderna: Authorized to begin Phase 1 trials for a Bundibugyo vaccine, using mRNA technology. Potential for significant revenue if successful.
Aug 01, 2026 · 301 articles
Accidents
Serum Institute of India: Manufactured a stockpile of 620,000 doses of the Oxford vaccine candidate. Its manufacturing capacity is crucial for potential large-scale deployment.
Moderna: Developed an mRNA-based Bundibugyo vaccine candidate, with Phase 1 trials starting in Canada. Its mRNA platform could offer a rapid response to emerging outbreaks.
Mar 09, 2018 · 543 articles
Accidents
Serum Institute of India: The Serum Institute of India is manufacturing doses of a vaccine candidate built on the University of Oxford/AstraZeneca platform, which could be used for clinical trials against the Bundibugyo ebolavirus.
Moderna: Moderna is one of the entities developing an experimental vaccine for the Bundibugyo virus, which could lead to future revenue and enhance its reputation in vaccine development.
May 18, 2026 · 505 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how Serum Institute of India and Moderna interact across events, view sentiment trends, and discover connected entities.
Open Dashboard